Immuno-Oncology

Intismeran autogene plus pembrolizumab improved recurrence-free survival and distant metastasis–free survival in resected stage IIB to IV melanoma.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, melanoma, ovarian cancer, prostate cancer, and hepatocellular carcinoma.

The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.

The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.

The FDA granted accelerated approval to RP1 plus nivolumab in anti–PD-1 therapy–pretreated advanced melanoma.

The Cellular, Tissue, and Gene Therapies Advisory Committee will review Replimune’s twice-rejected BLA for RP1 plus nivolumab in advanced melanoma.

Laurence J. DiNardo, MD, FACS, discusses ctDNA testing in head and neck cancers, advancements in targeted therapies, and multidisciplinary collaboration.

Matthew Galsky, MD, discusses the FDA approval of perioperative pembrolizumab plus enfortumab vedotin in MIBC.

The phase 3 OptiTROP-Lung06 trial showed a PFS improvement with sac-TMT plus pembrolizumab in PD-L1–negative NSCLC.

The top 5 OncLive TV videos of the week cover insights in breast cancer, lymphoma, melanoma, prostate cancer, and ovarian cancer.

The FDA has approved new sacituzumab govitecan indications in TNBC, cleared palbociclib combination maintenance treatment in HER2-positive breast cancer, and more.

BI-1808 as a single agent and in combination with pembrolizumab elicited responses and was generally well tolerated in patients with CTCL.

Prespecified biomarker analyses of ASCENT-03 and ASCENT-04 showed longer PFS with sacituzumab govitecan–based regimens vs comparators in TNBC.

Ultra-low-dose nivolumab plus oral metronomic chemotherapy cut the risk of death by 43% versus paclitaxel-carboplatin in first-line platinum-sensitive recurrent or metastatic HNSCC.

The FDA approved adjuvant atezolizumab for muscle-invasive bladder cancer with circulating tumor DNA molecular residual disease.

First-line INBRX-106 plus pembrolizumab generated a higher ORR vs pembrolizumab monotherapy in PD-L1–positive metastatic or unresectable HNSCC.

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.

Danvatirsen in combination with pembrolizumab did not result in an ORR improvement vs pembrolizumab alone in first-line recurrent/metastatic HNSCC.

Here is your cheat sheet to all oncology therapeutic options that were cleared or rejected by the FDA in April 2026.

The FDA grants priority review to enfortumab vedotin-ejfv sBLAs in MIBC, the review period for subcutaneous isatuximab BLA in myeloma has been extended, and more.

Pembrolizumab plus lenvatinib and belzutifan, as well as pembrolizumab/quavonlimab plus lenvatinib, did not extend OS or PFS in first-line ccRCC.

The FDA has granted priority review to the sBLAs for pembrolizumab and subcutaneous pembrolizumab plus enfortumab vedotin in cisplatin-eligible MIBC.

Sharon Castellino, MD, MSc, discusses the significance of the FDA approval of nivolumab plus AVD for stage III/IV classical Hodgkin lymphoma.

Tisotumab vedotin plus carboplatin & pembrolizumab ± bevacizumab achieved 65.8% ORR and 28-month median OS in first-line recurrent/metastatic cervical cancer.

The top 5 OncLive TV videos of the week cover insights in mantle cell lymphoma, chronic lymphocytic leukemia, salivary gland cancer, cholangiocarcinoma, and prostate cancer.